Alpha Therapeutic Corporation Sustainability Profile
Alpha Therapeutic Corporation, a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in the early 1980s, the company has established itself as a leader in the development and production of innovative therapies, particularly in the field of immunoglobulin products. With a strong focus on treating immune deficiencies and related disorders, Alpha Therapeutic is renowned for its high-quality plasma-derived therapies. The company’s commitment to excellence is reflected in its rigorous manufacturing processes and dedication to patient care. Over the years, Alpha Therapeutic has achieved significant milestones, solidifying its market position as a trusted provider of essential healthcare solutions. Its unique offerings and unwavering focus on research and development continue to set it apart in a competitive landscape.
DitchCarbon Score
How does Alpha Therapeutic Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alpha Therapeutic Corporation's score of 55 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alpha Therapeutic Corporation, headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is part of a corporate family that includes Grifols, S.A., from which it inherits emissions data and climate commitments. As a merged entity, Alpha Therapeutic Corporation aligns its climate initiatives with those of Grifols, S.A. However, specific reduction targets or achievements have not been disclosed. The company does not appear to have set Science-Based Targets Initiative (SBTi) reduction targets or other documented climate pledges at this time. In the context of the industry, Alpha Therapeutic Corporation's commitment to sustainability may be influenced by broader trends in the biopharmaceutical sector, where companies are increasingly focusing on reducing their carbon footprints and enhancing environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 85,532,000 | 00,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 113,055,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 64,761,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 |
How Carbon Intensive is Alpha Therapeutic Corporation's Industry?
How Carbon Intensive is Alpha Therapeutic Corporation's Location?
Alpha Therapeutic Corporation's Scope 3 Categories Breakdown
Alpha Therapeutic Corporation's Scope 3 emissions, which increased by 11% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 53% of Scope 3 emissions.
Top Scope 3 Categories
Alpha Therapeutic Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alpha Therapeutic Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
